Canine Mammary Tumors as a Potential Model for Human Breast Cancer in Comparative Oncology by Amirhossein Razavirad, Sanaz Rismanchi, Pejman Mortazavi, Ahad Muhammadnejad

“…In total, 64 canine mammary tumors were selected to study the most common markers, which are applicable for human breast cancer treatment, including estrogen and progesterone receptors (ER and PR), human epidermal growth factor (HER2/neu), Ki67, and cyclooxygenase 2 (Cox2). Immunohistochemistry (IHC) was used to assess the protein expression. …”
Get full text

Genetics of Endometrial Cancers by Tsuyoshi Okuda, Akihiko Sekizawa, Yuditiya Purwosunu, Masaaki Nagatsuka, Miki Morioka, Masaki Hayashi, Takashi Okai

“…In contrast, p53 mutations or Her2/neu overexpression are more frequent in non-endometrioid tumors. …”
Get full text

Practical Consequences Resulting from the Analysis of a 21-Multigene Array in the Interdisciplinary Conference of a Breast Cancer Center by Hans-Ullrich Voelker, Lea Frey, Annette Strehl, Michael Weigel

“…In 50 hormone- receptor-positive, Her2neu-negative carcinomas of the breast with no or only minimal lymph node involvement (max. pT1a) we initiated an Oncotype DX® multigene assay in addition to the evaluation of usual parameters. …”
Get full text

Paget’s disease of the breast: a contemporary perspective by O. O. Yemelyanova, A. D. Zikiryakhodzhaev, N. N. Volchenko, V. V. Efanov

“…Significant prognostic factors, e.g. the invasive component of Paget’s cancer, the involvement status of regional lymph nodes, morphological criteria, the grade of malignancy, overexpression of epidermal growth factor Her2/neu, the presence of BRCA 1/2 and CHEK2 gene mutations, as well as age, affect the prognosis of Paget’s disease. …”
Get full text

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience by C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, Sheldon Feldman

“…TargetPrint (TP) is an assay for assessing estrogen, progesterone, and HER2-neu receptor status based on mRNA expression. …”
Get full text

Radiological images of an advanced invasive carcinoma with mucinous aspects: A case report by Chiara Adriana Pistolese, MD, PhD, Francesca Di Giuliano, MD, PhD, Martina Cerocchi, MD, Maria Volpe, MD, Martina Cerasi Dellanea, MD, Flavia Briganti, MD, Paola Elda Gigliotti, MD, Carolina Goffredo, MD, Lucia Giudice, MD, Diletta Caccia, MD, Francesca Servadei, MD, Adriano De Majo, MD, PhD, Marco Materazzo, MD, Giorgio Pistilli, MD, Gianluca Vanni, MD, PhD, Valeria Liberto, MD

“…Immunohistochemistry study demonstrated ER positivity (95%), PR low (5%), HER-2-Neu negativity (score 0) and proliferative index (Ki67) of 20%, determining a Luminal B-like (HER 2-negative) subtype. …”
Get full text

Study of the effectiveness of vacuum-aspiration breast biopsy in patients with complete clinical response after neoadjuvant polychemotherapy in complex treatment of breast cancer by K. V. Maksimov, D. V. Bagdasarova, A. D. Zikiryakhodzhaev, A. A. Kolomeytseva, M. L. Mazo, V. S. Surkova, F. N. Usov, I. A. Eremeeva, A. N. Gerasimov

“…No statistically significant results of the association between complete pathomorphological response and the molecular-biological type of breast cancer were obtained (p > 0.05), however, there is a tendency towards the greatest number of complete pathomorphological responses in Her2-neu-positive (luminal – 100 %, non-luminal – 90.9 %) and triple-negative (87.50 %) types of breast cancer. …”
Get full text

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

“…Patients diagnosed with stage II–III, hormone-receptor-positive, HER2/neu negative breast cancer within 12 months of diagnosis had completed all definitive therapy aside from endocrine therapy (started within 6 months prior to study entry) were eligible. …”
Get full text